Maspin in thyroid cancer: its relationship with p53 and clinical outcome

  • Authors:
    • Carsten Boltze
    • Regine Schneider-Stock
    • Frank Meyer
    • Brigitte Peters
    • Claudia Quednow
    • Cuong Hoang-Vu
    • Albert Roessner
  • View Affiliations

  • Published online on: November 1, 2003     https://doi.org/10.3892/or.10.6.1783
  • Pages: 1783-1787
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The serine protease inhibitor maspin has been reported to inhibit invasiveness and motility of tumor cells. Additionally, a p53-dependent regulatory pathway of maspin in human cancer has been indicated. In a pre-study we were able to detect maspin protein in papillary thyroid carcinomas (PTC), whereas normal (tumor-free) thyroid tissue, follicular adenomas, follicular carcinomas, poorly differentiated carcinomas and undifferentiated carcinomas of the thyroid were maspin-negative. The first aim of our study was to determine the prognostic value of maspin protein expression for the recurrence-free and overall survival of PTC patients undergoing radical thyroidectomy and postoperative irradiation. Secondly, maspin expression was correlated to p53 protein expression in order to gain additional information on a possible regulatory influence of the wild-type p53 protein on maspin. An immunohistochemical approach study was performed on 68 tumor specimens. Maspin protein expression was detectable in 48 of 68 patients (71%; M+). After a median follow-up of 81 (26-117) months the median recurrence-free survival was 60 (28-117) months for M+ and 42 (11-108) months for M− (p=0.03). After 110 months 83% of patients had recurrence-free disease in M+, whereas in M− only 40% of patients were recurrence-free. The median long-term survival was 81 (42-108) months for M+ and 55 (21-99) months for M− (p=0.03). After 5 years, M+ and M− patients had a total survival of 98 and 80%, and after 9 years 90 and 60%, respectively. Mutant-type p53 expression was detectable in 17 of 68 PTC (25%). Mt p53 was positive in 1 of 47 M+ (2%) compared with 16 of 20 M− (80%, p<0.01). This study indicates that maspin protein possibly functions as a clinically relevant inhibitor of tumor progression, preventing local invasiveness and further systemic progression of papillary thyroid carcinomas. Our data hint of a p53-depentent regulatory pathway of the maspin protein in human cancer.

Related Articles

Journal Cover

November-December 2003
Volume 10 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Boltze C, Schneider-Stock R, Meyer F, Peters B, Quednow C, Hoang-Vu C and Roessner A: Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncol Rep 10: 1783-1787, 2003
APA
Boltze, C., Schneider-Stock, R., Meyer, F., Peters, B., Quednow, C., Hoang-Vu, C., & Roessner, A. (2003). Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncology Reports, 10, 1783-1787. https://doi.org/10.3892/or.10.6.1783
MLA
Boltze, C., Schneider-Stock, R., Meyer, F., Peters, B., Quednow, C., Hoang-Vu, C., Roessner, A."Maspin in thyroid cancer: its relationship with p53 and clinical outcome". Oncology Reports 10.6 (2003): 1783-1787.
Chicago
Boltze, C., Schneider-Stock, R., Meyer, F., Peters, B., Quednow, C., Hoang-Vu, C., Roessner, A."Maspin in thyroid cancer: its relationship with p53 and clinical outcome". Oncology Reports 10, no. 6 (2003): 1783-1787. https://doi.org/10.3892/or.10.6.1783